Skip to main content

Advertisement

SpringerLink
Log in

Macroscopic locoregional relapse from prostate cancer: which role for salvage radiotherapy?

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

Salvage radiotherapy (SRT) after radical prostatectomy for prostate cancer (PCa) is recommended as soon as PSA rises above 0.20 ng/ml, but many patients (pts) still experience local macroscopic relapse. The aim of this multicentric retrospective analysis was to evaluate the role of SRT in pts with macroscopic relapse.

Materials and methods

From 2001 to 2016, 105 consecutive pts with macroscopic PCa relapse underwent SRT ± androgen deprivation therapy (ADT). Mean age was 72 years. At time of relapse, 29 pts had a PSA value < 1.0 ng/mL, 50 from 1.1 to 5, and 25 pts > 5. Before SRT, 23 pts had undergone 18F-choline PET and 15 pts pelvic MRI. Ninety-four pts had prostatic bed relapse only, and four nodal involvement. Fifty-one pts were previously submitted to first-line ADT, while 6 pts received ≥ 2 lines.

Results

At a median follow-up of 52 months, 89 pts were alive, while 16 were dead. Total RT dose to macroscopic lesions was > 70 Gy in 58 pts, 66–70 Gy in 43, and < 66 Gy in 4 pts. In 72 pts, target volume encompassed only the prostatic bed with sequential boost to macroscopic site; 33 pts received prophylactic pelvic RT. Ten-year overall survival was 76.1%, while distant metastasis-free survival was 73.3%. No grade 4–5 toxicities were found.

Conclusions

SRT ± ADT for macroscopic relapse showed a favorable oncological outcome supporting its important role in this scenario. Data from this series suggest that SRT may either postpone ADT or improve results over ADT alone in appropriately selected pts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002;167:117–22.

    Article  Google Scholar 

  2. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–27.

    Article  Google Scholar 

  3. Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol. 2016;34(32):3864–71.

    Article  Google Scholar 

  4. Buergy D, Sertdemir M, Weidner A, Shelan M, Lohr F, Wenz F, et al. Detection of local recurrence with 3-Tesla MRI after radical prostatectomy: a useful method for radiation treatment Planning? vivo. 2018;32:125–31.

    CAS  Google Scholar 

  5. Panebianco V, Barchetti F, Sciarra A, Musio D, Forte V, Gentile V, et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol. 2013;23:1745–52.

    Article  Google Scholar 

  6. Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014;55:223–32.

    Article  CAS  Google Scholar 

  7. Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, et al. A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer. Eur Urol. 2018;73:156–65.

    Article  Google Scholar 

  8. TNM (2016) AJCC 8th Edition, Editor Brierley JD, Gospodarowicz MK, Wittekind C. ISBN: 978-1-119-26356-2.

  9. Shelan M, Abo-Madyan Y, Welzel G, Bolenz C, Kosakowski J, Behnam N, et al. Dose-escalated salvage radiotherapy after radical prostatectomy in high risk prostate cancer patients without hormone therapy: outcome, prognostic factors and late toxicity. Radiat Oncol. 2013;27(8):276. https://doi.org/10.1186/1748-717X-8-276.

    Article  Google Scholar 

  10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  CAS  Google Scholar 

  11. The National Cancer Institute Common Terminology Criteria for Adverse Events Scale, Version 4.0. May 2009, revised June 2010.

  12. Ravi P, Karnes RJ, Rangel LJ, Pagliaro LC. Outcomes and prognostic factors in men receiving androgen deprivation therapy for prostate cancer recurrence after radical prostatectomy. J Urol. 2018;200:1075–981.

    Article  Google Scholar 

  13. NCCN Guidelines, Version 1.2018.

  14. Borghetti P, Spiazzi L, Cozzaglio C, Pedretti S, Caraffini B, Triggiani L, et al. Postoperative radiotherapy for prostate cancer: the sooner the better and potential to reduce toxicity even further. Radiol Med. 2018;123(1):63–70.

    Article  Google Scholar 

  15. Umbehr MH, Muntener M, Hany T, Sulser T, Bachann LM. The role of 11c-choline and 18f-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64(1):106–17.

    Article  Google Scholar 

  16. Sandgren K, Westerlinck P, Jonsson JH, Blomqvist L, Thellenberg Karlsson C, Nyholm T et al. Imaging for the detection of locoregional recurrences in biochemical progression after radical prostatectomy-a systematic review. Eur Urol Focus. 2017. https://doi.org/10.1016/j.euf.2017.11.001.

    Article  Google Scholar 

  17. Kim BS, Lashkari A, Vongtama R, Lee SP, Parker RG. Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer. 2004;3:93–7.

    Article  Google Scholar 

  18. Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, et al. Multi-institutional evaluation of elective nodal irradiation and/or androgen deprivation therapy with postprostatectomy salvage radiotherapy for prostate cancer. Eur Urol. 2018;74(1):99–106.

    Article  Google Scholar 

  19. Pasquier D, Nickers P, Peiffert D, Maingon P, Pommier P, Lacornerie T, et al. Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: preliminary results of a multicenter phase II trial (CKNO–PRO). PLoS ONE. 2017;12(11):e0187794.

    Article  Google Scholar 

  20. Byun SJ, Kim YS, Ahn H, Kim CS. Image-guided, whole-pelvic, intensity modulated radiotherapy for biochemical recurrence following radical prostatectomy in high-risk prostate cancer patients. PLoS ONE. 2018;13:e0190479.

    Article  Google Scholar 

  21. Cotter SE, Chen MH, Moul JW, Lee WR, Koontz BF, Anscher MS, et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011;117:3925–32.

    Article  Google Scholar 

  22. Moschini M, Soria F, Briganti A, Shariat SF. The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients. Prostate Cancer Prostatic Dis. 2017;20:7.

    Article  CAS  Google Scholar 

  23. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–28.

    Article  Google Scholar 

  24. Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17:747–56.

    Article  CAS  Google Scholar 

  25. Maru S, Uchino H, Osawa T, Chiba S, Mour G, Sazawa A. Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy. PLoS ONE. 2018;13:e0197252.

    Article  Google Scholar 

Download references

Funding

No funding was foreseen to sustain this work

Author information

Authors and Affiliations

  1. Radiotherapy Unit, University Hospital of Modena, Via del Pozzo 71, 41100, Modena, Italy

    A. Bruni, B. Lanfranchi, L. Rubino, L. Frassinelli, F. Lohr & E. Mazzeo

  2. Radiotherapy Unit, “Tor Vergata” University General Hospital, Rome, Italy

    G. Ingrosso & R. Santoni

  3. Radiotherapy Unit, “Santa Maria” University Hospital, Terni, Italy

    F. Trippa & E. Maranzano

  4. Radiotherapy Unit, “Nuovo San Salvatore” Hospital, L’Aquila, Italy

    M. Di Staso & S. Parente

  5. Urology Unit, University Hospital of Modena, Modena, Italy

    M. C. Sighinolfi

Authors
  1. A. Bruni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Ingrosso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Trippa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Di Staso
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Lanfranchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Rubino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Parente
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Frassinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E. Maranzano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. Santoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. C. Sighinolfi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F. Lohr
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E. Mazzeo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Bruni.

Ethics declarations

Conflict of interest

Alessio Bruni was member of an Advisory Board for Astra Zeneca receiving a Grant. He also received a sponsorship from Ferring, Janssen and Astellas to participate to National and International Conference. He also received a speaker honorarium from Astra Zeneca. Gianluca Ingrosso declares he has no conflict of interests. Fabio Trippa declares he has no conflict of interests, Mario Di Staso declares he has no conflict of interests, Biancaluisa Lanfranchi declares he has no conflict of interests. Laura Rubino declares he has no conflict of interests; Silvia Parente declares he has no conflict of interest. Luca Frassinelli declares he has no conflict of interests. Ernesto Maranzano declares he has no conflict of interests. Riccardo Santoni declares he has no conflict of interests. Maria Chiara Sighinolfi declares he has no conflict of interests. Frank Lohr declares he has no conflict of interests. Ercole Mazzeo received an honorarium as expert from Janssen.

Ethical approval

All procedures performed in the study were in accordance with the ethical standards of the Institutional and National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent for the treatment proposed was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Appendix

Appendix

See Table 1.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bruni, A., Ingrosso, G., Trippa, F. et al. Macroscopic locoregional relapse from prostate cancer: which role for salvage radiotherapy?. Clin Transl Oncol 21, 1532–1537 (2019). https://doi.org/10.1007/s12094-019-02084-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-019-02084-0

Keywords

Search

Navigation